思创医惠欺诈发行余波未平被调查 扣非五年亏30.6亿苍南国资入主仍未落定

Core Viewpoint - The case of fraud in securities issuance involving Sichuang Medical Technology (300078.SZ) has resurfaced as the company is under investigation by the Hangzhou Public Security Bureau, with the company cooperating in the evidence collection process [2][3]. Financial Performance - Sichuang Medical Technology has reported continuous losses for five consecutive years from 2020 to 2024, with a total loss of 3.057 billion yuan. The company's revenues during these years were 1.375 billion yuan, 963 million yuan, 1.116 billion yuan, 1.006 billion yuan, and 691 million yuan, while net profits were 15.11 million yuan, -685 million yuan, -878 million yuan, -874 million yuan, and -502 million yuan respectively [7]. - In Q1 2025, the company achieved a revenue of 409 million yuan, a year-on-year increase of 105.78%, but still reported a net loss of 19.55 million yuan and a non-recurring net loss of 29.47 million yuan, although these figures represented a reduction in losses of 71.14% and 56.91% respectively [7]. Regulatory Actions - In early 2024, the company was fined 85.7 million yuan by the China Securities Regulatory Commission (CSRC) for financial fraud, with the former chairman receiving a 10-year market ban and a personal fine of 7.5 million yuan [5][6]. - The Shenzhen Stock Exchange imposed a five-year ban on accepting the company's listing application documents due to the violations [6]. Corporate Restructuring - Sichuang Medical Technology has taken steps to mitigate its situation by selling its subsidiary, Medical Technology Co., Ltd., for approximately 300 million yuan to a company controlled by the Cangnan County Finance Bureau [7][8]. - The Cangnan County Finance Bureau is also in the process of acquiring control of Sichuang Medical Technology, with plans to purchase shares from the current major shareholder [8]. Future Outlook - The completion of the transaction with Cangnan County Finance Bureau is expected to change the company's major shareholder and control structure, potentially leading to a restructuring of its business and compliance systems [8].